KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Non Operating Income (2023 - 2025)

Fulgent Genetics' Non Operating Income history spans 3 years, with the latest figure at $21.0 million for Q4 2025.

  • For Q4 2025, Non Operating Income fell 2.08% year-over-year to $21.0 million; the TTM value through Dec 2025 reached $21.1 million, down 4.06%, while the annual FY2025 figure was $21.1 million, 4.06% down from the prior year.
  • Non Operating Income for Q4 2025 was $21.0 million at Fulgent Genetics, up from -$5000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $21.4 million in Q4 2024 and bottomed at -$8.0 million in Q2 2025.
  • The 3-year median for Non Operating Income is $6.6 million (2023), against an average of $5.5 million.
  • The largest YoY upside for Non Operating Income was 99.93% in 2025 against a maximum downside of 72445.45% in 2025.
  • A 3-year view of Non Operating Income shows it stood at $6.6 million in 2023, then surged by 222.12% to $21.4 million in 2024, then decreased by 2.08% to $21.0 million in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Non Operating Income are $21.0 million (Q4 2025), -$5000.0 (Q3 2025), and -$8.0 million (Q2 2025).